15-Minute app could spot thinking problems in brain tumor patients

NCT ID NCT05504681

First seen Nov 15, 2025

Summary

This study is testing whether a 15-minute app called Brainlab Cognition can be used in busy brain tumor clinics to track memory, attention, and other thinking skills. Researchers will also collect quality-of-life reports electronically from patients. The goal is to see if this approach is practical and helpful for routine care. About 200 adults with brain tumors will participate.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BRAIN METASTASIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Miami Cancer Institute

    RECRUITING

    Miami, Florida, 33176, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to

If successful, this could make it routine to quickly check memory and thinking in brain tumor clinics, helping doctors spot problems earlier.

What could go wrong

This is an early observational study, not a treatment trial. The app may not be practical in busy clinics or may not capture meaningful changes.

Conditions

The condition(s) this trial relates to.

brain cancer central nervous system cancer cognitive disorder metastatic malignant neoplasm in the brain

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.